EUVIMEDEUVIMED entdecken
Open Access

Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms

Rohit Thummalapalli iD, Salomon Tendler iD, Joanne F Chou, Zeynep C Tarcan iD, Courtney Porfido, Jonathan Willner, Irina Linkov, Umesh Bhanot iD, Alissa J Cooper iD, Jierui Xu iD, James J Harding iD, Natasha Rekhtman iD und 13 weitere

JCO Precision Oncology · 2025-11 · (9)

DOI: 10.1200/po-25-00724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-11. Verfasst von Rohit Thummalapalli und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms, Intestinal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Delta-like ligand 3 (DLL3) is an emerging target across neuroendocrine cancers, but remains underexplored in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs), including poorly differentiated gastroenteropancreatic neuroendocrine carcinomas (GEP NECs) and well-differentiated neuroendocrine tumors (NETs). We aimed to define the landscape of DLL3 expression and feasibility of DLL3-targeted imaging in this population. PATIENTS AND METHODS We completed DLL3 immunohistochemistry (IHC) on 379 tumor samples from patients with GEP NENs, analyzing associations between DLL3 IHC positivity, clinicopathologic features, and outcomes. [ 89 Zr]Zr-DFO-SC16.56 DLL3 immuno-positron emission tomography-computed tomography (immunoPET-CT) imaging was performed in six patients with DLL3 IHC-positive advanced GEP NENs. RESULTS Among GEP NECs, DLL3 expression was identified in 55/78 (71%) tumors, was enriched for small cell histology, and did not demonstrate prognostic significance. Among well-differentiated gastroenteropancreatic neuroendocrine tumors, DLL3 expression was identified in 5/235 (2%) of grade 1-2 and 25/66 (40%) grade 3 (G3) tumors, most commonly G3 pancreatic NETs (PanNETs; 22/52, 43%), with univariate analysis revealing increased mortality risk among patients with DLL3-positive advanced G3 PanNETs (hazard ratio 3.27 [95% CI, 1.09 to 9.78]). Between May 28, 2024, and February 10, 2025, six patients with DLL3 IHC-positive GEP NENs underwent [ 89 Zr]Zr-DFO-SC16.56 immunoPET-CT imaging, which delineated DLL3-avid tumor lesions in five of six patients (two of two GEP NECs, three of four G3 PanNETs). Tumor-specific uptake of [ 89 Zr]Zr-DFO-SC16.56 varied between patients, with maximum standard uptake values ranging from 7.4 to 36.7, with four of six cases demonstrating DLL3 avidity in ≥50% of tumor lesions. CONCLUSION DLL3 is expressed on a majority of GEP NECs and on a subset of high-grade PanNETs marked by poor outcomes. Functional imaging suggests DLL3 as a promising therapeutic target in both GEP NECs and high-grade PanNETs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsIntestinal NeoplasmsIntracellular Signaling Peptides and ProteinsMembrane ProteinsHumansMaleFemaleMiddle AgedAgedPositron Emission Tomography Computed TomographyAdultImmunohistochemistry

Substanzen

DLL3 protein, humanIntracellular Signaling Peptides and ProteinsMembrane Proteins

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Pathology Core Facility, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Rohit Thummalapalli, Salomon Tendler, Zeynep C Tarcan, Umesh Bhanot, Alissa J Cooper, Jierui Xu, James J Harding, Natasha Rekhtman, Charles M Rudin, Yelena Y Janjigian, Heiko Schöder, Jinru Shia, Olca Basturk, Diane Reidy-Lagunes, Jason S Lewis, Lisa Bodei, Nitya Raj

Förderung

  • NCI NIH HHS

Zitieren

APA

Thummalapalli, R., Tendler, S., Chou, J. F., Tarcan, Z. C., Porfido, C., Willner, J., Linkov, I., Bhanot, U., Cooper, A. J., Xu, J., Harding, J. J., Rekhtman, N., Tang, L. H., Rudin, C. M., Janjigian, Y. Y., Schöder, H., Porier, J. T., Shia, J., Basturk, O., …, & Raj, N. (2025). Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. JCO Precision Oncology. https://doi.org/10.1200/po-25-00724

Vancouver

Thummalapalli R, Tendler S, Chou JF, Tarcan ZC, Porfido C, Willner J, et al. Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. JCO Precision Oncology. 2025. doi:10.1200/po-25-00724

BibTeX
@article{Thummalapalli2025,
  author = {Thummalapalli, Rohit and Tendler, Salomon and Chou, Joanne F and Tarcan, Zeynep C and Porfido, Courtney and Willner, Jonathan and Linkov, Irina and Bhanot, Umesh and Cooper, Alissa J and Xu, Jierui and Harding, James J and Rekhtman, Natasha and Tang, Laura H and Rudin, Charles M and Janjigian, Yelena Y and Schöder, Heiko and Porier, John T and Shia, Jinru and Basturk, Olca and Reidy-Lagunes, Diane and Capanu, Marinela and Lewis, Jason S and Bodei, Lisa and Dunphy, Mark P and Raj, Nitya},
  title = {Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-25-00724}
}
Kostenlos starten →